AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 123 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 4.38 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $5,620,715 | -79.6% | 1,979,125 | +5.9% | 0.10% | -84.0% |
| Q4 2023 | $27,513,520 | -44.1% | 1,869,125 | -30.5% | 0.61% | -62.6% |
| Q3 2023 | $49,233,265 | -53.2% | 2,688,873 | -44.8% | 1.64% | -46.0% |
| Q2 2023 | $105,130,433 | -40.6% | 4,873,919 | -19.2% | 3.04% | -41.8% |
| Q1 2023 | $177,056,455 | -21.3% | 6,034,644 | -0.9% | 5.23% | -17.2% |
| Q4 2022 | $224,963,904 | +46.0% | 6,088,333 | +11.3% | 6.32% | +41.3% |
| Q3 2022 | $154,038,000 | +125.9% | 5,472,033 | +54.6% | 4.47% | +109.3% |
| Q2 2022 | $68,188,000 | +260.0% | 3,540,408 | +140.2% | 2.14% | +463.6% |
| Q1 2022 | $18,942,000 | – | 1,474,107 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 5,472,033 | $154,038,000 | 4.47% |
| Ghost Tree Capital, LLC | 550,000 | $15,483,000 | 4.35% |
| Ghost Tree Capital, LLC | 500,000 | $14,075,000 | 3.95% |
| Bain Capital Life Sciences Investors, LLC | 1,023,214 | $28,803,000 | 3.44% |
| Boxer Capital, LLC | 2,084,000 | $58,665,000 | 3.30% |
| Alpha Wave Global, LP | 700,635 | $19,723,000 | 2.33% |
| Soleus Capital Management, L.P. | 429,336 | $12,086,000 | 1.64% |
| Ikarian Capital, LLC | 250,000 | $7,037,000 | 1.40% |
| Cormorant Asset Management, LP | 610,000 | $17,172,000 | 1.20% |
| SECTORAL ASSET MANAGEMENT INC | 205,400 | $5,782,000 | 1.14% |